Pooja Gokhale
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pooja Gokhale has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Lorenzo Villa Zapata
Department of Clinical and Administrative Pharmacy College of Pharmacy University of Georgia Athens Georgia USA
6 shared publications Akwasi Akosah
Department of Clinical and Administrative Pharmacy University of Georgia College of Pharmacy Athens Georgia USA
2 shared publicationsMichael Lim
Department of Clinical and Administrative Pharmacy University of Georgia College of Pharmacy Athens Georgia USA
2 shared publications- Akhila Yerubandi
Department of Clinical and Administrative Pharmacy College of Pharmacy University of Georgia Athens Georgia USA
1 shared publication - Akwasi Akosah
Department of Clinical and Administrative Pharmacy University of Georgia College of Pharmacy Athens Georgia USA
1 shared publication - Henry Nolan Young
Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Athens, GA, United States
1 shared publication
Latest Publications
- Open Access
Weight Loss With GLP ‐1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta‐Analysis
Objective: Two glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) (semaglutide and liraglutide) and one dual agonist (tirzepatide) are FDA‐approved for weight loss in adults with obesity without type 2 diabetes mellitus. This systematic review and network meta‐analysis aims to compare the efficacy of these agents against each other. Methods: A comprehensive search of PubMed/MEDLINE, Embase, Web of Science, and Cochrane Library was conducted from inception to May 2025. Phase 3 randomized controlled trials (RCTs) in adult patients (≥ 18 years) with at least one arm of tirzepatide, semaglutide, or liraglutide were included. A frequentist random‐effects network meta‐analysis was performed using R 4.3.3. Results: Of 1420 articles identified, 15 RCTs with 14,059 patients were included. All agents significantly reduced body weight compared to placebo. The largest reduction occurred with the maximum tolerated dose of tirzepatide, followed by tirzepatide 15 mg and 10 mg, semaglutide 2.4 mg, tirzepatide 5 mg, and liraglutide 3 mg. Tirzepatide and semaglutide were associated with a higher risk of any adverse event compared with placebo, whereas liraglutide was not. Conclusions: Tirzepatide, particularly at higher doses, provides the greatest weight reduction in adults without diabetes. Future studies should evaluate discontinuation, weight regain, metabolic outcomes, cost‐effectiveness, and patient preferences.
Open AccessWeight Loss With GLP ‐1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta‐Analysis
Objective: Two glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) (semaglutide and liraglutide) and one dual agonist (tirzepatide) are FDA‐approved for weight loss in adults with obesity without type 2 diabetes mellitus. This systematic review and network meta‐analysis aims to compare the efficacy of these agents against each other. Methods: A comprehensive search of PubMed/MEDLINE, Embase, Web of Science, and Cochrane Library was conducted from inception to May 2025. Phase 3 randomized controlled trials (RCTs) in adult patients (≥ 18 years) with at least one arm of tirzepatide, semaglutide, or liraglutide were included. A frequentist random‐effects network meta‐analysis was performed using R 4.3.3. Results: Of 1420 articles identified, 15 RCTs with 14,059 patients were included. All agents significantly reduced body weight compared to placebo. The largest reduction occurred with the maximum tolerated dose of tirzepatide, followed by tirzepatide 15 mg and 10 mg, semaglutide 2.4 mg, tirzepatide 5 mg, and liraglutide 3 mg. Tirzepatide and semaglutide were associated with a higher risk of any adverse event compared with placebo, whereas liraglutide was not. Conclusions: Tirzepatide, particularly at higher doses, provides the greatest weight reduction in adults without diabetes. Future studies should evaluate discontinuation, weight regain, metabolic outcomes, cost‐effectiveness, and patient preferences.
- Open Access
- 2 April 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (4) , e71777
Immune‐Related Adverse Events in Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors: Insights From a FAERS Disproportionality Analysis
Introduction: Immune checkpoint inhibitors (ICIs) are an important treatment option in bladder cancer, but clinical trials have demonstrated that they are associated with immune‐related adverse events (irAEs), such as rash, hypothyroidism, hyperthyroidism, and others. This study aimed to evaluate real‐world evidence of these irAEs using the FDA Adverse Event Reporting System (FAERS). Methods: We analyzed FAERS data through December 2024 to identify irAEs associated with atezolizumab, pembrolizumab, avelumab, and nivolumab in patients with bladder cancer. A case/non‐case pharmacovigilance analysis was conducted to assess the association between ICI monotherapy and specific irAEs, including rash, pruritus, hypothyroidism, hyperthyroidism, colitis, nephritis, myocarditis, pneumonitis, and myositis. Results: A total of 365 unique irAE reports were identified. Significant safety signals were observed for hyperthyroidism with atezolizumab (PRR: 3.51 [95% CI: 1.07–11.45]; ROR: 3.53 [95% CI: 1.07–11.61]; IC: 1.10 [95% CI: 0.33–1.87]), rash with pembrolizumab (PRR: 2.11 [95% CI: 1.17–3.80]; ROR: 2.14 [95% CI: 1.18–3.90]; IC: 0.44 [95% CI: 0.17–0.71]), and myositis with avelumab (PRR: 5.30 [95% CI: 1.35–20.82]; ROR: 5.47 [95% CI: 1.34–22.29]; IC: 1.95 [95% CI: 0.65–3.25]). While not reaching the threshold for statistical significance, nephritis with atezolizumab did not meet predefined signal detection criteria and should only be considered as hypothesis‐generating. A similar borderline pattern was observed for hypothyroidism with avelumab. Conclusion: The occurrence of irAEs varies by ICI agent among bladder cancer patients. These findings underscore the importance of post‐marketing surveillance in identifying real‐world safety signals. Proactive management and patient education are essential to mitigate irAEs and preserve quality of life.
- 2 April 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (4) , e71777
Open AccessImmune‐Related Adverse Events in Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors: Insights From a FAERS Disproportionality Analysis
Introduction: Immune checkpoint inhibitors (ICIs) are an important treatment option in bladder cancer, but clinical trials have demonstrated that they are associated with immune‐related adverse events (irAEs), such as rash, hypothyroidism, hyperthyroidism, and others. This study aimed to evaluate real‐world evidence of these irAEs using the FDA Adverse Event Reporting System (FAERS). Methods: We analyzed FAERS data through December 2024 to identify irAEs associated with atezolizumab, pembrolizumab, avelumab, and nivolumab in patients with bladder cancer. A case/non‐case pharmacovigilance analysis was conducted to assess the association between ICI monotherapy and specific irAEs, including rash, pruritus, hypothyroidism, hyperthyroidism, colitis, nephritis, myocarditis, pneumonitis, and myositis. Results: A total of 365 unique irAE reports were identified. Significant safety signals were observed for hyperthyroidism with atezolizumab (PRR: 3.51 [95% CI: 1.07–11.45]; ROR: 3.53 [95% CI: 1.07–11.61]; IC: 1.10 [95% CI: 0.33–1.87]), rash with pembrolizumab (PRR: 2.11 [95% CI: 1.17–3.80]; ROR: 2.14 [95% CI: 1.18–3.90]; IC: 0.44 [95% CI: 0.17–0.71]), and myositis with avelumab (PRR: 5.30 [95% CI: 1.35–20.82]; ROR: 5.47 [95% CI: 1.34–22.29]; IC: 1.95 [95% CI: 0.65–3.25]). While not reaching the threshold for statistical significance, nephritis with atezolizumab did not meet predefined signal detection criteria and should only be considered as hypothesis‐generating. A similar borderline pattern was observed for hypothyroidism with avelumab. Conclusion: The occurrence of irAEs varies by ICI agent among bladder cancer patients. These findings underscore the importance of post‐marketing surveillance in identifying real‐world safety signals. Proactive management and patient education are essential to mitigate irAEs and preserve quality of life.
- Open Access
- 11 December 2025
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (2) , 79-91
Immune-related adverse events associated with immune checkpoint inhibitor therapy in bladder cancer patients: A systematic review and meta-analysis
- 11 December 2025
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (2) , 79-91
Open AccessImmune-related adverse events associated with immune checkpoint inhibitor therapy in bladder cancer patients: A systematic review and meta-analysis
- Open Access
- 26 June 2025
- Published by Elsevier in American Journal of Infection Control
Opioid use and risk of Clostridioides difficile infection in hospitalized patients: A systematic review and meta-analysis
- 26 June 2025
- Published by Elsevier in American Journal of Infection Control
Open AccessOpioid use and risk of Clostridioides difficile infection in hospitalized patients: A systematic review and meta-analysis
- 10 February 2025
- Published by SAGE Publications in Journal of Huntington's Disease
- Vol. 14 (1) , 30-42
Economic burden of Huntington’s disease: A systematic review
Background: Huntington's disease (HD) is an autosomal dominant neurodegenerative disease, characterized by progressive motor, cognitive, and psychiatric symptoms. The disease poses a significant social and economic burden. Objective: This systematic review aims to characterize the global economic burden by analyzing the direct, indirect, and total costs associated with HD. Methods: A comprehensive literature search was conducted across PubMed/MEDLINE, Web of Science, and Cochrane Library from inception to June 2024. The titles and abstracts were screened independently by two reviewers and full-text, English-language articles assessing direct, indirect, and/or total costs of HD were included. The costs were converted to annual costs in 2024 United States Dollars (USD). Results: Out of the initial 608 de-duplicated articles, 19 full-text articles were included. The articles spanned 44 years, from 1980 to 2024. The studies covered a total of 15 countries. Annual costs in 2024 USD ranged significantly by region: Americas ($2542-$90,515), Europe ($40,000-$215,020), Asia ($1915-$7132), and Oceania ($3678-$8721). The highest costs were reported in Norway ($171,842) and the UK ($215,020), while Asian countries reported substantially lower costs (China: $6469; South Korea: $6305; Taiwan: $1915-$7132). Conclusions: The global economic burden of HD varies substantially across regions, influenced by prevalence rates, healthcare systems, and reporting methodologies. Study limitations include heterogeneous cost reporting methods, potential underestimation in cost conversions, and lack of disease severity stratification. Standardizing cost-of-illness study methodologies and developing specific quality assessment tools would enhance cross-study comparability and improve resource allocation globally.
- 10 February 2025
- Published by SAGE Publications in Journal of Huntington's Disease
- Vol. 14 (1) , 30-42
Economic burden of Huntington’s disease: A systematic review
Background: Huntington's disease (HD) is an autosomal dominant neurodegenerative disease, characterized by progressive motor, cognitive, and psychiatric symptoms. The disease poses a significant social and economic burden. Objective: This systematic review aims to characterize the global economic burden by analyzing the direct, indirect, and total costs associated with HD. Methods: A comprehensive literature search was conducted across PubMed/MEDLINE, Web of Science, and Cochrane Library from inception to June 2024. The titles and abstracts were screened independently by two reviewers and full-text, English-language articles assessing direct, indirect, and/or total costs of HD were included. The costs were converted to annual costs in 2024 United States Dollars (USD). Results: Out of the initial 608 de-duplicated articles, 19 full-text articles were included. The articles spanned 44 years, from 1980 to 2024. The studies covered a total of 15 countries. Annual costs in 2024 USD ranged significantly by region: Americas ($2542-$90,515), Europe ($40,000-$215,020), Asia ($1915-$7132), and Oceania ($3678-$8721). The highest costs were reported in Norway ($171,842) and the UK ($215,020), while Asian countries reported substantially lower costs (China: $6469; South Korea: $6305; Taiwan: $1915-$7132). Conclusions: The global economic burden of HD varies substantially across regions, influenced by prevalence rates, healthcare systems, and reporting methodologies. Study limitations include heterogeneous cost reporting methods, potential underestimation in cost conversions, and lack of disease severity stratification. Standardizing cost-of-illness study methodologies and developing specific quality assessment tools would enhance cross-study comparability and improve resource allocation globally.
- Open Access
- 12 September 2024
- Published by Wiley in Hematological Oncology
- Vol. 42 (5) , e3308
Bruton tyrosine kinase inhibitor monotherapy in B‐cell lymphoma and risk of infection: A systematic review and meta‐analysis of randomized controlled trials
Bruton's tyrosine kinase (BTK) inhibitors are important therapeutic advances with promising efficacy outcomes in the treatment of patients with chronic lymphocytic leukemia and other B‐cell lymphoma subtypes. However, the utility of BTK inhibitors can be limited by adverse events such as infections. In this systematic review and meta‐analysis, we aim to determine the risk of various infections associated with BTK inhibitor monotherapy in B‐cell lymphoma patients. A comprehensive search was conducted in MEDLINE/PubMed, Embase, and Web of Science databases from their inception until October 2023. ClinicalTrials.gov, bibliographies, and relevant conference abstracts were also searched for additional records. Randomized controlled trials that included any B‐cell lymphoma patients treated with BTK inhibitor monotherapy and reported infection were included. Meta‐analysis was performed to calculate risk ratio (RR) using a random‐effects model in R Statistical Software, version 4.3.2. Of 3292 studies retrieved, we included 12 studies in this systematic review and meta‐analysis. The median age of patients across the study arms ranged between 64 and 73 years. The overall pooled RR for any grade upper respiratory tract infections (URTI) associated with BTK inhibitor treatment was 1.55 (95% Confidence Interval (CI) 1.22–1.97). The RR of grade ≥3 URTI was reported in 14 out of 1046 patients, yielding an RR of 1.46 (95% CI 0.61–3.54), which was not statistically significant. The pooled RR of any grade pneumonia was 1.20 (95% CI 0.68–2.10) and grade ≥3 pneumonia was 1.12 (95% CI 0.67–1.85), both of which were not statistically significant. Patients with B‐cell lymphoma who are undergoing BTK inhibitor monotherapy face an elevated risk of developing URTI. Clinicians prescribing BTK inhibitors should be aware of the potential infectious events that may occur. Close monitoring and the implementation of effective prophylactic measures are essential for managing these patients.
- 12 September 2024
- Published by Wiley in Hematological Oncology
- Vol. 42 (5) , e3308
Open AccessBruton tyrosine kinase inhibitor monotherapy in B‐cell lymphoma and risk of infection: A systematic review and meta‐analysis of randomized controlled trials
Bruton's tyrosine kinase (BTK) inhibitors are important therapeutic advances with promising efficacy outcomes in the treatment of patients with chronic lymphocytic leukemia and other B‐cell lymphoma subtypes. However, the utility of BTK inhibitors can be limited by adverse events such as infections. In this systematic review and meta‐analysis, we aim to determine the risk of various infections associated with BTK inhibitor monotherapy in B‐cell lymphoma patients. A comprehensive search was conducted in MEDLINE/PubMed, Embase, and Web of Science databases from their inception until October 2023. ClinicalTrials.gov, bibliographies, and relevant conference abstracts were also searched for additional records. Randomized controlled trials that included any B‐cell lymphoma patients treated with BTK inhibitor monotherapy and reported infection were included. Meta‐analysis was performed to calculate risk ratio (RR) using a random‐effects model in R Statistical Software, version 4.3.2. Of 3292 studies retrieved, we included 12 studies in this systematic review and meta‐analysis. The median age of patients across the study arms ranged between 64 and 73 years. The overall pooled RR for any grade upper respiratory tract infections (URTI) associated with BTK inhibitor treatment was 1.55 (95% Confidence Interval (CI) 1.22–1.97). The RR of grade ≥3 URTI was reported in 14 out of 1046 patients, yielding an RR of 1.46 (95% CI 0.61–3.54), which was not statistically significant. The pooled RR of any grade pneumonia was 1.20 (95% CI 0.68–2.10) and grade ≥3 pneumonia was 1.12 (95% CI 0.67–1.85), both of which were not statistically significant. Patients with B‐cell lymphoma who are undergoing BTK inhibitor monotherapy face an elevated risk of developing URTI. Clinicians prescribing BTK inhibitors should be aware of the potential infectious events that may occur. Close monitoring and the implementation of effective prophylactic measures are essential for managing these patients.